In patients with T1D, cannabinoid hyperemesis syndrome and diabetic gastroparesis have similar symptoms but different ...

Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal ...

Researchers from Washington University School of Medicine and Stanford University have developed a compound that simulates a ...

Despite the controversial attitude towards cannabis, its use is recognized in many states. However, American laws vary ...

Evidence is stacking up about the influence of cannabinoids on cardiovascular disease, and newer, synthetic options are ...

Synthetic cannabinoids, a class of new psychoactive substances, bind to cannabinoid receptors CB1 and CB2 much more strongly than tetrahydrocannabinol (THC) and cannabidiol (CBD), raising public ...

VIP36, a new CB1 agonist, targets a cryptic pocket to provide analgesia for chronic pain while minimizing side effects and ...

The way they did it was to design a custom, synthetic cannabinoid molecule that is positively charged, which prevents it from being able to cross the blood-brain barrier. This means it can’t bind to ...

Discover how terpenes work synergistically with cannabinoids to enhance medicinal effects, offering therapeutic benefits beyond what CBD and THC provide alone.

A receptor that cannabis latches onto in the brain could be a promising target for future mental health treatments.

Endocannabinoids are lipid mediators that interact with G protein-coupled receptors, including cannabinoid CB2 receptor (CB2R), which is mainly expressed in peripheral tissues with immune functions.